Objective: Information about rivaroxaban plasma level (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban. Methods: In a multicenter registry-based study (Novel Oral Anticoagulants in Stroke Patients collaboration; ClinicalTrials.gov: NCT02353585) of patients with stroke while taking rivaroxaban, we compared RivLev in patients with AIS and ICH. We determined how many AIS patients had RivLev 100ng/ml, indicating possible eligibility for thrombolysis, and how many ICH patients had RivLev 75ng/ml, making them possibly eligible for the use of specific reversal agents. We explored factors associated with RivLev (Spearman correlation, regression models) and studied the View this article online at wileyonlinelibrary.com.
sensitivity and specificity of international normalized ratio (INR) thresholds to substitute RivLev using cross tables and receiver operating characteristic curves. Results: Among 241 patients (median age 5 80 years, interquartile range [IQR] 5 73-84; median time from onset to admission 5 2 hours, IQR 5 1-4.5 hours; median RivLev 5 89ng/ml, IQR 5 31-194), 190 had AIS and 51 had ICH. RivLev was similar in AIS patients (82ng/ml, IQR 5 30-202) and ICH patients (102ng/ml, IQR 5 51-165; p 5 0.24). Trough RivLev (137ng/ml) occurred in 126/190 (66.3%) AIS and 34/51 (66.7%) ICH patients. Among AIS patients, 108/190 (56.8%) had RivLev 100ng/ml. In ICH patients, 33/51 (64.7%) had RivLev 75ng/ml. RivLev was associated with rivaroxaban dosage, and inversely with renal function and time since last intake (each p < 0.05). INR 1.0 had a specificity of 98.9% and a sensitivity of 25.7% to predict RivLev 100ng/ml. INR 1.4 had a sensitivity of 59.3% and specificity of 90.1% to predict RivLev 75ng/ml. Interpretation: RivLev did not differ between patients with AIS and ICH. Half of the patients with AIS under rivaroxaban had a RivLev low enough to consider thrombolysis. In ICH patients, two-thirds had a RivLev high enough to meet the eligibility for the use of a specific reversal agent. INR thresholds perform poorly to inform treatment decisions in individual patients. ANN NEUROL 2018; 83:451-459 R ivaroxaban is an inhibitor of factor Xa in the coagulation cascade with rapid onset of the anticoagulant effect. 1 The peak plasma levels are expected 2 to 6 hours after intake, whereas trough levels occur after 10 to 14 hours. 2, 3 However, these figures were based on measurements in healthy volunteers or patients with deep venous thrombosis rather than acute stroke. Furthermore, plasma levels might be influenced by factors such as impaired renal function, advanced age, and concomitant medication, 2, 4 and interindividual variance can be large. 2, 4 Assessing the anticoagulant effect of rivaroxaban is challenging, as its influence on standard coagulation tests is limited. 5 More recently, drug-specific coagulation tests measuring the rivaroxaban plasma level (RivLev) have been available. 6 Measuring the anticoagulant activity of rivaroxaban in individual patients with acute ischemic stroke (AIS) and acute intracerebral hemorrhage (ICH) may influence treatment decisions to use or refrain from thrombolysis 7, 8 or specific reversal agents. 9, 10 However, there exists considerable clinical uncertainty around patients taking rivaroxaban presenting with AIS or ICH regarding acute treatment decisions, as the anticoagulant activity in individual patients is often not known, which might lead to delayed or denied treatment options. Measurement of RivLev may show whether AIS patients have a low RivLev, whereas patients with ICH have a high RivLev, but it remains to be clarified whether there is an association between RivLev and type of stroke. It is unknown how many AIS patients may possibly qualify for thrombolysis and how many ICH patients possibly meet the eligibility criteria for treatment with specific reversal agents if RivLev is taken into account. It is also unclear whether in AIS and ICH patients RivLev might be associated with clinical characteristics, such as renal function. Finally, if measurement of RivLev is not available, it remains unknown whether international normalized ratio (INR) is a sufficiently accurate substitute of RivLev to inform therapeutic decisions in individual patients.
In this large, international, multicenter collaboration, we have therefore analyzed RivLev in patients with AIS or ICH using rivaroxaban to answer the following questions: (1) Does the distribution of RivLev differ between patients with AIS and those with ICH? (2) How many AIS patients had RivLev 100ng/ml, indicating being possibly eligible for thrombolysis, and how many ICH patients had RivLev 75ng/ml, meeting the eligibility criteria for the use of specific reversal agents? (3) How is RivLev influenced by renal function, time since last intake, dosage of rivaroxaban, age, or sex? (4) Can the INR be used to estimate RivLev and inform clinical decisions?
Subjects and Methods

Study Design and Study Population
We performed a cohort study at centers participating in the international, multicenter Novel Oral Anticoagulants in Stroke Patients (NOACISP) collaboration. 11 Data from local registries were used to identify patients with AIS or ICH who were treated with rivaroxaban at the time of stroke onset and who had RivLev measured on hospital admission. Details on participating centers, number of patients contributed, type of registry, and recruitment period are summarized in Supplementary  Table 1 .
Ethics
The NOACISP registry as a multicenter collaboration (ClinicalTrials.gov: NCT02353585) was approved by the ethics committee in Basel, Switzerland (EKNZ 2014-027). The requirement for additional local ethical approval differed among participating centers and was acquired by the local principal investigator if necessary.
Data Collection
Data were collected as in prior published research studies. 11, 12 Briefly, local investigators filled in standardized forms with predefined variables [11] [12] [13] [14] using individual patient data from local prospective registries. Completed forms were collected at the coordinating center in Basel, where the pooled analysis was performed. The corresponding author had full access to all the data in the study and takes responsibility for its integrity and the data analysis.
Baseline and Follow-up Data
The following baseline variables were recorded: age, sex, stroke severity on admission as assessed by the National Institutes of Health Stroke Scale (NIHSS), 15 location of ICH (deep or lobar), time since last intake (ie, time of last intake to time of stroke center admission), time since symptom onset, and time of hospital admission.
The following risk factors were collected, applying definitions used in prior research [11] [12] [13] [14] : atrial fibrillation, hypertension, diabetes mellitus, hypercholesterolemia, coronary artery disease, and previous use of antiplatelet drugs, antihypertensive drugs, or statins.
Measurement of Drug-Specific Rivaroxaban Plasma Levels and Laboratory Measures
All coagulation tests including RivLev were performed as part of routine assessment in participating centers. Blood draw for all laboratory tests was done immediately after admission and admission time was taken as the time point of RivLev measurement, as done in prior research. 16 All centers used commercially available assays to determine RivLev (DiXal, HYPHEN BioMed, Neuville-sur-Oise, France was used by the following centers: Basel, Paris, Z€ urich, Baden, St Gallen, Verona, Lausanne, Bern, Reggio Emilia; Liquid Anti-Xa, Stago, Asnières-sur-Seine, France was used by: Dijon, Lille, Annecy; and HemosIL Liquid Anti-Xa, Instrumentation Laboratory, Bedford, MA was used by the center in Modena). We applied the following definitions for different RivLev categories, which had been reported for patients using 20mg of rivaroxaban once daily 2 :
RivLev trough 137ng/ml, RivLev intermediate 5 138 to 183ng/ml, RivLev peak 5 184 to 343ng/ml, and RivLev very high > 343ng/ml. Additionally, we used 2 cutoff values with potential clinical implications: (1) RivLev 100ng/ml, a threshold previously suggested 7 and applied 11, 17 to select patients taking rivaroxaban for thrombolysis; and (2) RivLev 75ng/ml, the lowest threshold applied in the pivotal trial on andexanet alfa, 10 a targeted reversal agent for rivaroxaban, to select patients with a relevant concentration of rivaroxaban suitable for effective use of this specific reversal agent. We then calculated the number of patients eligible from our cohort for (1) thrombolysis (RivLev 100ng/ml), using the INR threshold with the highest specificity (assuming clinicians chose the maximum of safety); and (2) andexanet treatment (RivLev > 75ng/ml), using the INR threshold with the highest Youden index (specificity 1 sensitivity 2 1) for maximum effectiveness. Furthermore, we collected data on standard laboratory measurements of INR (central laboratory measurement) and renal function as quantified by the glomerular filtration rate estimated by the Chronic Kidney Disease Epidemiology collaboration equation as done in prior stroke research.
12,18
Statistics
Group comparison between patients with AIS and those with ICH was performed using the chi-square test for categorical variables and the Mann-Whitney U test for continuous variables. Correlations were tested with Spearman test.
Univariate linear censored regression models (Tobit models 19 ) were constructed with RivLev as dependent parameter. Age, sex, time since last intake (continuous variable), renal function (continuous variable), dosage of rivaroxaban, type of stroke (AIS vs ICH), and NIHSS were included as independent parameters. RivLev was left-censored at detection level (20ng/ ml) and log transformed prior to analysis. The estimates and 95% confidence interval (CI) are presented back transformed to the original scale, therefore indicating an approximatively multiplicative effect.
To assess the accuracy of the INR to identify RivLev of 100ng/ml and 75ng/ml, receiver operating characteristic curves were constructed and the area under the curve (AUC) was calculated. Sensitivity and specificity of the different INR cutoffs (1.0, 1.1, 1.2, and 1.4 for 100ng/ml and 1.0, 1.1, 1.2, and 1.4 for 75ng/ml) were calculated using cross tables.
All tests were 2-tailed, and statistical significance was determined at an a-level of 0.05. Statistical analyses were performed using SPSS, version 23.0, for Windows (IBM, Armonk, NY) and R. 20 
Results
Study Population
Our study population comprised 241 patients with AIS (n 5 190) or ICH (n 5 51). The median delay between AIS or ICH onset and admission was 2.0 hours (IQR 5 1.0-4.5 hours). In 187 patients (77.6%) the last intake of rivaroxaban was within 24 hours before admission, and in another 36 (14.9%) the last intake was within 48 hours before admission. In the remaining 18 patients (7.5%), the last intake was >48 hours before admission or unknown.
Baseline Characteristics
Baseline characteristics for all patients are displayed in the 
RivLev
The median RivLev was similar in patients with AIS (82ng/ml, IQR 5 30-202ng/ml) and those with ICH (102ng/ml, IQR 5 51-165ng/ml, p 5 0.24).
Distribution of different RivLev categories is displayed in Figure 1 . The majority of patients had RivLev trough(137ng/ml) in both groups, with no statistical significant difference ( 
RivLev and INR
We observed a correlation between RivLev and INR (Spearman rho 5 0.66, p < 0.001; see Fig 2D) . Overall, predictive ability of the INR was good, with an AUC of 0.830 (95% CI 5 0.773-0.888; Fig 3A) for RivLev 100ng/ml and 0.843 (95% CI 5 0.786-0.899; see Fig 3B) for RivLev 75ng/ml. The sensitivity to predict RivLev 100ng/ml with INR 1.0/1.1/1.2/1.4 was 25.7%/42.9%/74.3%/90.5%, and specificity was 98.9%/89.4%/83.0%/55.3%. The sensitivity to predict RivLev 75ng/ml with INR 1.0/1.1/1.2/1.4 was 100%/97.5%/89.0%/59.3%, whereas the specificity was 4.9%/39.5%/59.3%/90.1%.
Cross tables indicating true and false negative and positive according to different INR thresholds are displayed in Supplementary Table 2 .
Using INR thresholds to select patients for clinical decisions would result in the following eligibility of patients among our study population. The INR 1.0 threshold, with the highest specificity yielding a maximum of safety, results in only 27 of 105 patients (25.7%) with RivLev 100ng/ml being eligible for FIGURE 3: Receiver operating characteristic curves to predict rivaroxaban plasma levels of (A) £ 100ng/ml and (B) 75ng/ml using the international normalized ratio and specificity (spec.) and sensitivity (sens.) for different predefined thresholds. CI 5 confidence interval; AUC 5 area under the curve.
thrombolysis. The INR threshold of INR 1.4, to select patients with the maximum of efficacy for andexanet treatment, results in 70 of 118 patients (59.3%) with RivLev 75ng/ml being eligible for effective rivaroxaban reversal.
Discussion
This multicenter, international observational study yields the following key findings: (1) RivLev did not differ between patients with AIS and ICH taking rivaroxaban; in both AIS and ICH patients, two-thirds of patients have low RivLev, whereas one-quarter of patients have high RivLev; (2) RivLev seems useful for the decision whether to use or refrain from thrombolysis or specific reversal agents, as thrombolysis would possibly be allowed in 56.8% of patients with AIS otherwise not eligible for thrombolysis, and only 64.7% of patients with ICH possibly qualify for effective reversal agent treatment; (3) measured RivLev was associated with rivaroxaban dosage and inversely with renal function and time since last intake; and (4) RivLev was associated with the INR, but our data do not support the use of INR as a substitute for RivLev to inform treatment decisions in individual patients. Counterintuitively, RivLev does not differ between AIS and ICH patients taking rivaroxaban, with a low RivLev present in two-thirds of the AIS as well as the ICH patients. The high percentage of low RivLev among AIS patients is analogous to similar findings among vitamin K antagonist (VKA) patients. 21 Here, subtherapeutic INR values were associated with an increased risk of AIS, 21 indicating that insufficient anticoagulant effects may have contributed to or triggered the ischemic stroke in patients with both types of anticoagulants. Interestingly, more than one-quarter of the ischemic stroke patients had their stroke at peak or even higher RivLev. Whether this is due to noncardioembolic stroke etiologies needs to be analyzed in further studies. Whereas the risk of ICH in patients taking VKA is associated with higher INR values (in particular > 3.0), 21, 22 about two-thirds of our ICH patients had low RivLev. This seeming discrepancy finding suggests that ICH in patients taking rivaroxaban is not necessarily promoted by high or peak drug levels. Our results suggest the importance of additional mechanisms other than a direct vasonoxious effect of anticoagulants 23 like the underlying vessel disease that will lead to the bleeding. More than half of the ICH patients with low RivLev had lobar ICH, possibly indicating the presence of an underlying cerebral amyloid angiopathy, which might explain why these patients bled despite relatively low RivLev. Two-thirds of patients with AIS had low RivLev, with potentially clinical implications. More than half of these patients had RivLev < 100ng/ml and would be potentially eligible for thrombolysis. These patients would be ineligible for thrombolysis without RivLev measurement according to current guidelines. 8 Our data
show that excluding categorically all patients taking rivaroxaban from intravenous thrombolysis seems not to be justified, as a majority of these patients would possibly be eligible. Likewise, two-thirds of patients with ICH had low RivLev, which means that not all patients with ICH may necessarily require the use of a reversal agent like andexanet alfa. In the study on andexanet alfa, 10 a recombinant modified human factor Xa decoy protein, 20 of 67 patients who received andexanet were excluded from the efficacy population analysis due to baseline RivLev < 75ng/ml. 10 Transferring this cutoff to our study population, 18 of 51 patients with ICH (35%) had RivLev of < 75ng/ml on admission and would thus not qualify for effective andexanet alfa treatment. Thus, a potentially unnecessary overuse might be an issue if andexanet is to be given to all patients irrespective of its actual anticoagulant activity. This means that measuring RivLev in patients with AIS and ICH has the potential to guide individual treatment decisions. Although commercial assays for RivLev measurement are available, they are yet lacking broad availability. The idea that results in clinical practice are not available fast enough to guide clinical decisions is widespread. Nevertheless, it has been shown that results can be obtained within around 30 minutes. 16 Thus, the development of specific point-of-care devices for novel oral anticoagulants including rivaroxaban (eg, ClincialTrials.gov: NCT02825394) can lead to a shorter time to treatment in patients with stroke under rivaroxaban. If they prove to be reliable and gain market authorization, they will make measurement of RivLev broadly available and more rapid. Given that two-thirds of ICH patients have elevated RivLev, making them eligible for reversal agent treatment, one can argue that in all ICH patients taking rivaroxaban, treatment should be given without any delay of waiting for RivLev measurement. A similar approach might be imaginable for the use of thrombolysis in those AIS patients otherwise eligible for thrombolysis.
Taking into account the limitations of our study, in particular the purely observational design, the currently limited evidence of the thresholds used, and the limited information about potential confounders (eg, presence vs absence of amyloid angiopathy), we are cautious regarding conclusions for clinical practice. There is insufficient certainty with regard to safety to recommend treating patients with AIS with thrombolysis or ICH patients with reversal agents, irrespectively of the RivLev, although such scenarios might evolve in the future.
The RivLev suggesting safe thrombolysis (ie, < 100ng/ml) in AIS differs from the RivLev meeting the eligibility criteria for reversal in the scenario of ICH (75ng/ml). Interestingly, a similar gap exists also in patients on VKA for whom thrombolysis is regarded as safe if the INR is <1.7 in patients with AIS, 24 whereas in the scenario of ICH associated with VKA, rapid correction of the INR is warranted if the INR is >1.2.
25,26
In patients taking rivaroxaban for treatment of deep vein thrombosis, RivLev is modulated by time since last intake, dosage of rivaroxaban, and renal function. 2 Our data add to these findings that the same variables are also the key factors influencing RivLev in patients with AIS or ICH taking rivaroxaban. RivLev correlated well with INR values in our population, confirming recent research findings. 27, 28 In addition, we tested the sensitivity and specificity of the INR to predict 2 clinically important RivLev thresholds. To identify patients with RivLev 100ng/ml for thrombolysis 7, 17 Our study has the following strengths: (1) to the best of our knowledge, we report on the largest yet available dataset of patients with AIS or ICH and measured rivaroxaban plasma levels; (2) the data from the participating centers were extracted from prospective registries that are ascertained independently from the current research questions, which is an argument against bias; (3) in our study, the mean time delay between symptom onset and admission to a participating center was only 2 hours; this short delay is an advantage, as the measured RivLev is likely to reflect the RivLev in the patient at symptom onset; and (4) furthermore, we report on a comprehensive dataset including clinical data, RivLev, and other laboratory analysis.
Nevertheless, our study has the following limitations: (1) although we report on a relatively large dataset, the overall numbers are still insufficient for multivariate analysis; (2) measurement of RivLev was not standardized throughout all center and different calibrators, and assays were used; nevertheless, all these assays/calibrators are licensed and certified; (3) in our analysis, we used the threshold of 75ng/ml for the use of specific reversal agents, as this threshold was used in the pivotal trial on andexanet alfa 10 ; nevertheless, this may be considered arbitrary, and other thresholds such as 50ng/ml 29 and even lower 9 have been proposed; (4) although the threshold of <100ng/ml to select patients for thrombolysis is reported in literature, 7 the clinical evidence for this approach is limited; this cutoff is based on theoretical considerations on available pharmacokinetic data on rivaroxaban 2 ; first clinical data 11, 17, 30 suggest that this threshold might be clinically useful, although it is still to be considered arbitrary because confirmative studies are currently missing; and (5) nearly half of the patients in this study are from a single center, which might affect generalizability.
In conclusion, our data indicate that in a substantial number of patients with AIS, thrombolysis may be safely applicable, whereas a substantial number of patients with ICH may not meet the eligibility criteria for the use of specific reversal agents. RivLev is dependent on time since last intake, dosage of rivaroxaban, and renal function. Although INR correlates well with RivLev, our data do not support the use of INR to substitute RivLev to inform treatment decisions in individual patients.
Boehringer Ingelheim, BMS, Daiichi Sankyo, and Pfizer produce anticoagulants. Stago produces a calibrated antifactor Xa assay to measure rivaroxaban plasma levels. The Bayer Foundation is linked to Bayer AG, producer of anticoagulants.
